How tiny amyloid clumps form under body-like conditions
Nanoscale assembly of amyloid oligomers at physiologically relevant conditions
This work looks at how the Alzheimer-related protein Aβ42 begins to stick together on cell membranes under conditions like those in the human brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11311150 on NIH RePORTER |
What this research studies
Many lab experiments force amyloid proteins to clump at concentrations far higher than what is found in the brain, which may miss how clumps form in people. This project focuses on how Aβ42 molecules assemble into small, potentially toxic oligomers at the low (nanomolar) concentrations that occur in vivo by studying their interactions with surfaces and cell membranes. The team uses nanoscale imaging, biophysical measurements, and theoretical models to observe and explain membrane-catalyzed aggregation pathways. Understanding these early steps could point to ways to prevent harmful oligomer formation before large plaques develop.
Who could benefit from this research
Good fit: This is primarily a laboratory project that does not require enrolling patients, though people with Alzheimer’s disease or at risk for it would be the eventual beneficiaries of the findings.
Not a fit: Patients seeking immediate symptom relief or ready-to-use treatments are unlikely to gain direct benefit from this basic-mechanism research in the short term.
Why it matters
Potential benefit: If successful, this could reveal how toxic amyloid oligomers form and suggest new targets to prevent or slow Alzheimer’s disease at an early stage.
How similar studies have performed: Previous laboratory studies have shown amyloid aggregation at high concentrations and some evidence supports membrane-driven oligomer formation, but testing these pathways at physiologically low concentrations is relatively novel.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Lyubchenko, Yuri L — University of Nebraska Medical Center
- Study coordinator: Lyubchenko, Yuri L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.